ResMed Inc.

RMD Healthcare Medical Instruments & Supplies

ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025. In the quarter to June 2026, revenue grew 8.58%, EPS grew 2.32%, free cash flow fell 21.3% and total debt fell 39.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.

238.97 3.26 −1.35%
Market cap
$34.1B
P/E
22.8×
Fwd P/E
16.6×
Dividend yield
1.03%
F-score
6/9
Altman Z
10.00
Beneish M
−2.59
Dividend safety
96/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

27.90 23.73 21.58 18.63
P/S ratio
7.61 6.51 5.89 5.02
P/FCF ratio
22.78 19.77 18.79 17.41
P/Operating CF
87.50 103.40 58.88 62.38
P/B ratio
6.54 5.56 5.03 4.31
EV/Sales
7.43 6.32 5.66 4.83
EV/EBITDA
19.67 16.52 14.55 12.81
EV/FCF
22.22 19.20 18.07 16.76
Current Ratio
2.89 3.06 3.01 3.10
Net Debt/EBITDA
(1.93) (1.83) (2.21) (2.12)
Debt/Equity
0.07 0.06 0.06 0.06
Earnings Yield
3.58% 4.21% 4.63% 5.37%
Free Cash Flow Yield
4.39% 5.06% 5.32% 5.74%
Free Cash Flow per Share
2.82 2.09 3.54 2.73
Book value per Share
41.87 43.34 44.67 45.25
Free Cash Flow
411.54 305.19 514.54 397.38
EV/EBIT
22.38 18.76 16.58 14.46
Other line items

Show all line items

Columns are period end dates